{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:05:22Z","timestamp":1786982722573,"version":"build-2736575974"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T00:00:00Z","timestamp":1639440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T00:00:00Z","timestamp":1639440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Teva Pharmaceutical Industries Ltd., Tel Aviv, Israel"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s40120-021-00309-5","type":"journal-article","created":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T05:02:52Z","timestamp":1639458172000},"page":"435-448","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Real-World Adherence to Tetrabenazine or Deutetrabenazine Among Patients With Huntington\u2019s Disease: A Retrospective Database Analysis"],"prefix":"10.1007","volume":"11","author":[{"given":"Daniel O.","family":"Claassen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev","family":"Ayyagari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Garcia-Horton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,14]]},"reference":[{"key":"309_CR1","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1002\/mds.25075","volume":"27","author":"T Pringsheim","year":"2012","unstructured":"Pringsheim T, Wiltshire K, Day L, Dykeman J, Steeves T, Jette N. The incidence and prevalence of Huntington\u2019s disease: a systematic review and meta-analysis. Mov Disord. 2012;27:1083\u201391.","journal-title":"Mov Disord"},{"key":"309_CR2","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/B978-0-12-381328-2.00014-6","volume":"98","author":"A Reiner","year":"2011","unstructured":"Reiner A, Dragatsis I, Dietrich P. Genetics and neuropathology of Huntington\u2019s disease. Int Rev Neurobiol. 2011;98:325\u201372.","journal-title":"Int Rev Neurobiol"},{"key":"309_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/currents.RRN1260","volume":"3","author":"JM Burgunder","year":"2011","unstructured":"Burgunder JM, Guttman M, Perlman S, Goodman N, van Kammen DP, Goodman L. An international survey-based algorithm for the pharmacologic treatment of chorea in Huntington\u2019s disease. PLoS Curr. 2011;3:RRN1260.","journal-title":"PLoS Curr"},{"key":"309_CR4","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s40271-018-0312-x","volume":"11","author":"EM Thorley","year":"2018","unstructured":"Thorley EM, Iyer RG, Wicks P, et al. Understanding how chorea affects health-related quality of life in Huntington disease: an online survey of patients and caregivers in the United States. Patient. 2018;11:547\u201359.","journal-title":"Patient"},{"key":"309_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.gene.2014.11.022","volume":"556","author":"A Kumar","year":"2015","unstructured":"Kumar A, Kumar Singh S, Kumar V, Kumar D, Agarwal S, Rana MK. Huntington\u2019s disease: an update of therapeutic strategies. Gene. 2015;556:91\u20137.","journal-title":"Gene"},{"key":"309_CR6","unstructured":"XENAZINE\u00ae (tetrabenazine) [package insert]. Fontaine-les-Dijon: Recipharm Fontaine SAS; 2017."},{"key":"309_CR7","unstructured":"Austedo\u00ae (deutetrabenazine) tablets [prescribing information]. Parsippany: Teva Pharmaceuticals USA, Inc.; 2020."},{"key":"309_CR8","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1358\/dnp.2010.23.6.1426638","volume":"23","author":"L Shao","year":"2010","unstructured":"Shao L, Hewitt MC. The kinetic isotope effect in the search for deuterated drugs. Drug News Perspect. 2010;23:398\u2013404.","journal-title":"Drug News Perspect"},{"key":"309_CR9","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1517\/13543776.2014.943184","volume":"24","author":"GS Timmins","year":"2014","unstructured":"Timmins GS. Deuterated drugs: where are we now? Expert Opin Ther Pat. 2014;24:1067\u201375.","journal-title":"Expert Opin Ther Pat"},{"key":"309_CR10","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1002\/j.1552-4604.1986.tb03544.x","volume":"26","author":"PD Klein","year":"1986","unstructured":"Klein PD, Klein ER. Stable isotopes: origins and safety. J Clin Pharmacol. 1986;26:378\u201382.","journal-title":"J Clin Pharmacol"},{"key":"309_CR11","doi-asserted-by":"publisher","first-page":"422","DOI":"10.5334\/tohm.287","volume":"6","author":"J Jankovic","year":"2016","unstructured":"Jankovic J, Jimenez-Shahed J, Budman C, et al. Deutetrabenazine in tics associated with Tourette syndrome. Tremor Other Hyperkinet Mov (N Y). 2016;6:422.","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"key":"309_CR12","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1017\/S1092852918001219","volume":"23","author":"SM Stahl","year":"2018","unstructured":"Stahl SM. Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other? CNS Spectr. 2018;23:239\u201347.","journal-title":"CNS Spectr"},{"key":"309_CR13","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2147\/DDDT.S138828","volume":"12","author":"M Dean","year":"2018","unstructured":"Dean M, Sung VW. Review of deutetrabenazine: a novel treatment for chorea associated with Huntington\u2019s disease. Drug Des Dev Ther. 2018;12:313\u20139.","journal-title":"Drug Des Dev Ther"},{"key":"309_CR14","doi-asserted-by":"publisher","first-page":"214","DOI":"10.3371\/CSRP.CUPR.010318","volume":"11","author":"MA Cummings","year":"2018","unstructured":"Cummings MA, Proctor GJ, Stahl SM. Deuterium tetrabenazine for tardive dyskinesia. Clin Schizophr Relat Psychoses. 2018;11:214\u201320.","journal-title":"Clin Schizophr Relat Psychoses"},{"key":"309_CR15","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/cts.12754","volume":"13","author":"F Schneider","year":"2020","unstructured":"Schneider F, Bradbury M, Baillie TA, et al. Pharmacokinetic and metabolic profile of deutetrabenazine (TEV-50717) compared with tetrabenazine in healthy volunteers. Clin Transl Sci. 2020;13:707\u201317.","journal-title":"Clin Transl Sci"},{"key":"309_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40734-017-0051-5","volume":"4","author":"DO Claassen","year":"2017","unstructured":"Claassen DO, Carroll B, De Boer LM, et al. Indirect tolerability comparison of deutetrabenazine and tetrabenazine for Huntington disease. J Clin Mov Disord. 2017;4:3.","journal-title":"J Clin Mov Disord"},{"key":"309_CR17","unstructured":"Symphony Health. IDV\u00ae fact sheet 2020. https:\/\/symphonyhealth.prahs.com\/insights\/idv-fact-sheet. Accessed August 27, 2021."},{"key":"309_CR18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1377\/hlthaff.2009.1087","volume":"30","author":"MC Roebuck","year":"2011","unstructured":"Roebuck MC, Liberman JN, Gemmill-Toyama M, Brennan TA. Medication adherence leads to lower health care use and costs despite increased drug spending. Health Aff (Millwood). 2011;30:91\u20139.","journal-title":"Health Aff (Millwood)"},{"key":"309_CR19","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1196\/annals.1425.007","volume":"1136","author":"C Hoffman","year":"2008","unstructured":"Hoffman C, Paradise J. Health insurance and access to health care in the United States. Ann N Y Acad Sci. 2008;1136:149\u201360.","journal-title":"Ann N Y Acad Sci"},{"key":"309_CR20","unstructured":"Aetna. Covered and non-covered drugs: drugs not covered\u2014and their covered alternatives. 2020 advanced control plan\u2014Aetna formulary exclusions drug list; 2020. http:\/\/www.aetna.com\/individuals-families\/document-library\/jan20-exclusion-drug-list.pdf. Accessed August 27, 2021."},{"key":"309_CR21","unstructured":"Express Scripts. 2019 Express Scripts national preferred formulary for Missouri consolidated health care plan; 2019. https:\/\/www.express-scripts.com\/art\/pdf\/MH3A-formulary.pdf. Accessed August 27, 2021."}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-021-00309-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-021-00309-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-021-00309-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T11:24:38Z","timestamp":1645183478000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-021-00309-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,14]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["309"],"URL":"https:\/\/doi.org\/10.1007\/s40120-021-00309-5","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,14]]},"assertion":[{"value":"13 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}